Navigation Links
ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced that the dividend to be paid on December 18, 2012, to holders of Chess Depositary Instruments (CDIs) trading on the Australian Securities Exchange will be Australian dollar $0.01636 per CDI. 

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed previously declared a quarterly dividend of US dollar $0.17 per share, which had a record date of November 20, 2012, and will be payable on December 18, 2012.  The dividend will be paid in US currency to holders of its common stock trading on the New York Stock Exchange (NYSE). 

The dividend paid in Australian currency to CDI holders reflects the exchange rate on the record date, which was US dollars $1.0389 for each Australian dollar $1.00, and reflects the 10:1 ratio between CDIs and US common shares listed on the NYSE. 

About ResMed
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Further information can be obtained by contacting Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Website at www.resmed.com

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Website.


'/>"/>
SOURCE ResMed Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
2. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
3. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
4. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
5. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
6. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
7. Vasomedical Announces Financial Results for the Third Quarter of 2012
8. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
9. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
10. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
11. ShangPharma Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Hutchison China MediTech (Chi-Med) ... the highly lucrative global oncology and immunology markets. ... first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, ... partners. HCM,s profitable Chinese healthcare business continues to ... progress of the mid-to-late-stage pipeline during 2016-17 (including ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology:
(Date:5/31/2016)... Linda, CA (PRWEB) , ... May 31, 2016 , ... ... both a primary screening tool and as an orthogonal tool for RNAi hit validation. ... highly functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in ...
(Date:5/31/2016)... Aviv (PRWEB) , ... May 31, 2016 , ... ... the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 ... and publishes a series of research reports evaluating these innovative vendors and their ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE Media Group , ... has added Cancer and Careers to its Advocacy Spotlight Partnership ... continuing successful careers while fighting cancer. , As partners, both organizations will supply ...
(Date:5/30/2016)... Lake City, Utah (PRWEB) , ... May 30, ... ... insurance reimbursement for small businesses, announced today the publication of an original infographic, ... business owners and health insurance professionals understand how Zane Benefits complies with various ...
(Date:5/29/2016)... Carolina (PRWEB) , ... May 29, 2016 , ... Whole ... via Amazon.com, their new KlipPro KP-240L clipper is available to the public. This is ... which is substantially wider than the average clipper. , Everything about this product is ...
Breaking Medicine News(10 mins):